HYPERCHOLESTEROLEMIA · White paper
Hypercholesterolemia Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About hypercholesterolemia — and why its trials are hard
Hypercholesterolemia, chiefly elevated low-density lipoprotein cholesterol (LDL-C), is a leading modifiable driver of atherosclerotic cardiovascular disease, the top global cause of death. It may be primary/genetic, including familial hypercholesterolemia (about 1 in 250 people), or secondary to diet, metabolic disease, and lifestyle, and affects roughly 12% of U.S. adults. The causal link between LDL-C and cardiovascular events is among the best-established in medicine, validated by decades of trials from statins onward. Therapy is tiered: high-intensity statins first, then ezetimibe, PCSK9 monoclonal antibodies, the siRNA inclisiran, and bempedoic acid for statin-intolerant patients. Trials use LDL-C reduction as the pivotal biomarker endpoint and major adverse cardiovascular events (MACE) as the hard outcome, with ApoB and Lp(a) as emerging markers. Key development challenges include the very large samples and long follow-up needed to demonstrate outcome benefit, residual risk despite aggressive LDL lowering, adherence, and the repeated failure of the CETP-inhibitor class to translate HDL changes into clinical benefit.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Atorvastatin (Lipitor) | 1996 | First-line LDL lowering (HMG-CoA reductase inhibitor) | ASCOT-LLA / CARDS | LDL-C reduction and major cardiovascular events | ~40-50% LDL-C reduction; significant reduction in coronary events (statin class landmark: 4S showed ~30% mortality reduction) |
| Ezetimibe (Zetia) | 2002 | Add-on to statin (cholesterol absorption inhibitor) | IMPROVE-IT (NCT00202878) | Composite MACE added to simvastatin | LDL-C lowered further to ~54 mg/dL; ~6% relative MACE reduction (HR 0.936) |
| Evolocumab (Repatha) | 2015 | High-risk ASCVD/FH add-on (PCSK9 monoclonal antibody) | FOURIER (NCT01764633) | Composite of cardiovascular events (MACE) | ~59% LDL-C reduction; 15% relative MACE reduction (HR 0.85) |
| Alirocumab (Praluent) | 2015 | Post-acute coronary syndrome / FH (PCSK9 monoclonal antibody) | ODYSSEY OUTCOMES (NCT01663402) | Composite MACE after acute coronary syndrome | ~55-60% LDL-C reduction; 15% relative MACE reduction (HR 0.85), with lower all-cause death |
| Inclisiran (Leqvio) | 2021 | Add-on for ASCVD/FH (PCSK9 siRNA, twice-yearly dosing) | ORION-9/10/11 | LDL-C reduction | ~50% LDL-C reduction with twice-yearly subcutaneous dosing |
| Bempedoic acid (Nexletol) | 2020 | Statin-intolerant or add-on (ACL inhibitor) | CLEAR Outcomes (NCT02993406) | LDL-C reduction; MACE in statin-intolerant patients | ~21% LDL-C reduction; 13% relative MACE reduction (HR 0.87) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in hypercholesterolemia development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Torcetrapib (CETP inhibitor) — ILLUMINATE (NCT00134264) | Increased cardiovascular events and mortality despite raising HDL and lowering LDL | Off-target blood-pressure/aldosterone effects; HDL-raising did not confer benefit |
| Evacetrapib (CETP inhibitor) — ACCELERATE (NCT01687998) | Terminated for futility; no cardiovascular benefit despite favorable lipid changes | CETP inhibition failed to translate lipid effects into outcomes |
| Dalcetrapib (CETP inhibitor) — dal-OUTCOMES (NCT00658515) | No significant reduction in cardiovascular events | Reinforced doubts about CETP/HDL as a therapeutic target |
Choosing the right endpoint
Primary endpoints that matter in hypercholesterolemia trials
- LDL-C reduction — Primary biomarker endpoint; causal and dose-dependent driver of ASCVD risk
- Major adverse cardiovascular events (MACE) — Hard clinical endpoint requiring large samples and long follow-up
- Apolipoprotein B (ApoB) — Emerging marker of atherogenic particle number; typically a secondary endpoint
- Lipoprotein(a) [Lp(a)] — Independent genetic risk factor; target of newer investigational agents
- Non-HDL cholesterol — Composite atherogenic lipid measure useful in mixed dyslipidemia
How iNGENū runs hypercholesterolemia trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Hypercholesterolemia clinical trials — FAQs
Why is LDL-C the main endpoint in cholesterol trials?
How much benefit do PCSK9 inhibitors add on top of statins?
Why did CETP inhibitors repeatedly fail?
Ready to discuss your hypercholesterolemia trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal